<SEC-DOCUMENT>0001144204-13-010542.txt : 20130221
<SEC-HEADER>0001144204-13-010542.hdr.sgml : 20130221
<ACCEPTANCE-DATETIME>20130221171346
ACCESSION NUMBER:		0001144204-13-010542
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130221
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130221
DATE AS OF CHANGE:		20130221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVELOS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-119366
		FILM NUMBER:		13631321

	BUSINESS ADDRESS:	
		STREET 1:		ONE GATEWAY CENTER, SUITE 504
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02458
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		ONE GATEWAY CENTER, SUITE 504
		CITY:			NEWTON
		STATE:			MA
		ZIP:			02458

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v335880_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 0; margin-bottom: 0">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<HR ALIGN="CENTER" NOSHADE SIZE="1" STYLE="color: Black; width: 25%; margin-top: 0; margin-bottom: 0">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report: February 21, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOVELOS THERAPEUTICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Exact name of registrant as specified
in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: windowtext 1pt solid; padding-right: 0.2in; padding-left: 0.2in; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: windowtext 1pt solid; padding-right: 0.2in; padding-left: 0.2in; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>333-119366</B></FONT></TD>
    <TD STYLE="width: 2%; font-weight: bold; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: windowtext 1pt solid; padding-right: 0.2in; padding-left: 0.2in; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>04-3321804</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>(State or other jurisdiction</I></FONT></TD>
    <TD STYLE="font-style: italic; text-align: center">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>(Commission</I></FONT></TD>
    <TD STYLE="font-style: italic; text-align: center">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>(IRS Employer</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>of incorporation)</I></FONT></TD>
    <TD STYLE="font-style: italic; text-align: center">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>File Number)</I></FONT></TD>
    <TD STYLE="font-style: italic; text-align: center">&nbsp;</TD>
    <TD STYLE="font-style: italic; text-align: center"><FONT STYLE="font-size: 10pt"><I>Identification Number)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>One Gateway Center, Suite 504</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Newton, MA 02458</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(617) 244-1616</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Registrant's telephone number, including
area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold"><FONT STYLE="font-size: 10pt; color: black"><B>ITEM 7.01</B></FONT></TD>
    <TD STYLE="width: 88%; font-weight: bold"><FONT STYLE="font-size: 10pt; color: black"><B>REGULATION FD DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A copy of the press release issued by us
on February 21, 2013 announcing the closing of the previously disclosed $5.5 million registered public offering of units consisting
of our common stock and warrants to purchase our common stock is furnished as Exhibit 99.1 and is incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; font-weight: bold"><FONT STYLE="font-size: 10pt; color: black"><B>ITEM 9.01 </B></FONT></TD>
    <TD STYLE="width: 88%; font-weight: bold"><FONT STYLE="font-size: 10pt; color: black"><B>FINANCIAL STATEMENTS AND EXHIBITS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Number</FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 82%; border-bottom: black 1pt solid; text-align: justify"><FONT STYLE="font-size: 10pt; color: black">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: black">99.1</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; color: black">Press Release dated February 21, 2013 entitled &ldquo;</FONT>Novelos Therapeutics Closes $5.5 Million Public Offering<FONT STYLE="color: black">&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>Dated: February 21, 2013</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><B>NOVELOS THERAPEUTICS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="font-style: italic; text-decoration: none; border-bottom: Black 1pt solid"><I>/s/ Harry S. Palmin</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Harry S. Palmin</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 16%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt; color: black">Number</FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 82%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt; color: black">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt; color: black">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt; color: black">Press Release dated February 21, 2013 entitled &ldquo;</FONT>Novelos Therapeutics Closes $5.5 Million Public Offering<FONT STYLE="color: black">&rdquo;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v335880_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><IMG SRC="tex99-1logo.jpg" ALT=""></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">NOVELOS THERAPEUTICS CLOSES $5.5 MILLION
PUBLIC OFFERING</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wisc. (February 21, 2013)</B>
&ndash; <B>Novelos Therapeutics, Inc. (OTCQX: NVLT)</B>, a pharmaceutical company developing novel drugs for the treatment and
diagnosis of cancer, today announced the closing of a public offering of 11,000,000 units at $0.50 per unit for gross proceeds
of $5,500,000. Each unit consisted of one share of our common stock, a Class A Warrant with a one-year term to purchase one-half
of a share of our common stock at an exercise price of $0.50 per share and a Class B Warrant with a five-year term to purchase
one share of our common stock at an exercise price of $0.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Burrill Securities LLC acted as a placement
agent in a co-lead capacity for the offering. Dawson James Securities, Inc. acted as a sub-agent in a co-lead capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Benchmark Company, LLC acted as a sub-agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This announcement shall not constitute
an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer or sale of these securities
in any jurisdiction or to any person in any particular jurisdiction in which such offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of such jurisdiction. The offering was made only by means of
a prospectus supplement and accompanying prospectus, copies of which may be obtained from Burrill Securities LLC, Prospectus Department,
One Embarcadero Center, Suite 2700, San Francisco, CA 94111, 415-591-5400 or email: <U>ksheinerman@b-c.com</U>. Before any investment,
an investor should read the prospectus supplement and the accompanying prospectus, including the information incorporated by reference
therein, for more complete information about Novelos and this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">J. Patrick Genn, Vice President of IR, Novelos Therapeutics,
Inc., Madison, Wisc. &amp; Boston, Mass., Ph: (858) 775-7456, Email: <U>jpgenn@novelos.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anne Marie Fields, Senior Vice President, LHA, Ph: (212) 838-3777,
Email: <U>afields@lhai.com</U>, @LHA_IR_PR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements. You can identify these statements by our use of words such as &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plans,&rdquo;
or their negatives or cognates.&nbsp;&nbsp;Such statements are valid only as of today, and we disclaim any obligation to update
this information. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on
our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk.
Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and
retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the
completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators&rsquo;
ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing
and third-party reimbursement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I># # #</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tex99-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tex99-1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/0"K`P$1``(1`0,1`?_$`:(````&`@,!````````
M``````<(!@4$"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+
M$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,7
M4G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R
M9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8
MF9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1
M``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B
M%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756
M-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>W
MQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:
M``P#`0`"$0,1`#\`VHOY9W\RW:7S>VG7;.W<V(VG\C=APS+O':-*YIL?N[$4
ME0*1-^[*IZB:6>3%SR,BU]'KDEQM2X!)ADAD:8/=;VJO>0+U;ZRUS<KW!'A2
M')C8BO@RD"FH9T-0!U'\08#'SV*]\]N]U=M;;=R,5OSK:`^-"N%F0&GCP`DG
M2<"1*DQL1Q5E)M6]P_UD'U[W[KW7O?NO=5!?'3^:_0?(#YN;U^&D71M=M6IV
M=G.V\*W8,O8%-EZ?('JO)UN->I7;2;2Q\M,,V:/6JFM<T^JQ+VO[FOF?V<DY
M;Y"M^>&W!9DGCMW\'P2I'U"JU-?B-71JI70*T\NL;^2?O"P\Y>Z5W[:+M36\
MEK/=Q_4&X#AOI6=:^'X*TUZ*T\0Z:^=.K??<*=9(=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW1>?EU_V2A\G/\`Q7ON?_WW&Y/8GY*_Y7+:
M?^EG:_\`5].@5[D_].[W[_I2WO\`VC2]40_\)L?^9:_*C_P^.L/_`'FMR^\A
M?O2_\E39_P#GGG_X_'UB;]R'_DB\P?\`/5;?\=GZV9/>*?6<_7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U\TOJ?+=T['[`S/<W1C[FQVZ.CY9.P\ENG;$+U,NT,&
MFX*/`R9G-TZ!UFVQ45^9@HJ])HY*22&J,=0/$[>^JF]0[#N&V)L7,/A-:;@/
M!6.0T$CZ"^E3Y.`I9""&!6JFH'7"_EJXYJVG>I>9^4O'6^VL_4/)$*F)!(L9
M=QG],M(J.&!0A]+@JQ!WCOY;O\Q/8?SOZP\DO\/VKWGLJAI(NT.NTJ`/4VBG
MCWIM..:1JJNV9F:DV!.J7'U+?;3DGQ2S\_O=+VQW'V[W:@U3<OW#'Z>:GY^%
M)3`E4?8'7N7\2KU@]D?>G9_=O8-=4@YJMD`NK>OV#QH@34PN?M,;'0Q(*.]D
MWN+.IPZ][]U[K3Q_EQ_]OQ>[?_#Y^7?_`+T^;]YN>Z/_`$X';_\`GFV[_JVG
M7-7V0_\`$JMW_P">W=O^KLW6X=[PCZZ5=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW1>?EU_V2A\G/\`Q7ON?_WW&Y/8GY*_Y7+:?^EG:_\`
M5].@5[D_].[W[_I2WO\`VC2]40_\)L?^9:_*C_P^.L/_`'FMR^\A?O2_\E39
M_P#GGG_X_'UB;]R'_DB\P?\`/5;?\=GZV9/>*?6<_7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]UII?R`,9CLU\Q^^\+F*"CRN'R_QWWKB\MB\C30UN.R>-K^Q]ATM
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M`^>W6OSNZDBW;MTTVW.R]LPT-!VKUI)5>6OVKFYXW$>1QIDTSY/9^=>"23'U
MEN0K0RZ9XI%&,ON1[=;K[>;T;*ZK+M4I)MYZ8D4?A;R61*@.OV,M5(/6:'L[
M[O;'[M\N#<K+3#OD`5;NVK5HG/XEKEH7()C?[4:CJ1T?3W'74N]:>/\`+C_[
M?B]V_P#A\_+O_P!Z?-^\W/='_IP.W_\`/-MW_5M.N:OLA_XE5N__`#V[M_U=
MFZV,?FG\_N@/@QM2@R_:^6K<KN_<<%7+LKK':L=/7;RW1]I^W+6B"HGIZ/";
M?@J2(Y<A6210!KI$)I1XCC#R'[;\R>X-XT&S(J641'BSR5$4=?*H!+N1D(H)
M\SI7/6:WNC[P\G^T^W)=<Q2-)N,P/@VT5&FEI^*A("1@X,CD"M0H9AIZ"[^6
MI\_,O_,`VAV]OJMZUH.L\3L3?]!M+;^+IMPU.YJZNH*K`4V8>KR^2DQF(I?O
MDDJ`I2"`(H_)^OLV]U/;F'VWOK+;DNFNYKBV,CL4"`$.5HJZF-,<2:]$7L?[
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MQ30EPYBD0UTE@JZ@R,DBG2,.`14'HVV0R%#B:"NRN3JZ>@QN,HZG(9"NJY4@
MI:*AHX7J:NKJ9I"L<-/301L[LQ`55)/L%Q1R32+#$I:5V`4#)))H`!YDG`ZD
M6::*VA>XG94@C4LS$T"JHJ22>``%2?(=4W?#?^;S1?,KOW>?5^TNBJC:G6.P
ML#O+>FYNZ=P]BT:XO$['V]5/1X3.Y+"2;5H8<?-N2:2%_#+D`*6G\\C.X@:\
MX\\>RLG(W+D&[7FX";=KF2**.U2$ZFE<59%82$L$%<A.XZ10:AUC1[9_>.B]
MS.;[K8=NVHV^PV<4TTM[)<T5((S17=#"H4N2M5,O8"S58(>BO_)/_A0CL3:>
M\*[8WQ:ZBG[I:BKI,;%O_<N5K]O[8SE9%(T1.T=N8S&5NY<_CY)%M%43/0&8
M>J.-D*NPMY6^[5N-[8KN/-UZ+`,NKP44/(H_X8[,$1O4`/3S(..@#SQ]\G:-
MMW1]HY"VX[H4<I]1(S1QNW#]*-5,CJ3@,S1D^2TH2'/5?_"B+-XO=U'M[Y/_
M`!EJ-GXBJEA%;F]@9+,QYW!TLTBI_$)=C[THJ:IR]+&MV;Q9"*0J#H21K*33
M=_NRV\UDUSRENPGF`-$F5=#D>7BQ$A3]J$>I`ST2[!]\^YM]S6QY\V,VULQ&
MJ2!F#Q@GXC#-\0XD_JJ:`T!..KONZ>T=@]T_!+O3M#K#<V-WAL7>7QH[ARVW
M\_BY&>FJZ63KG<R212Q2+'445?15"/#4TTR1U%-41O%*BR(RB`MAVC<=B]Q-
MNVC=HF@W"#=;971N(/C)P\B"*%6!(8$$$@@]94<U;_M'-'M'N^_;#.ESM-SL
M5Z\<B\"/II000:%64@JRL`RL"K`$$=4P?\)L?^9:_*C_`,/CK#_WFMR^YT^]
M+_R5-G_YYY_^/Q]8R?<A_P"2+S!_SU6W_'9^CZ?.K^<)\>OACG*_K;'X[(=S
M]TX^.-LKLC:^2H\9@]H23P^6GAWON^HAKH,5D'1T?[&FIJRL6-@94A#(S1W[
M>^R7,O/5NNZRLMCL+'MED4L\E#0F*,$:E\M;,JU^$M0TEOW9^\IR;[8W3['`
MC[IS2@[H(F"I$2*@334;2W`Z$1W`(UA*@FJVF_X4.?(7'5,&XMR_$':R=>U$
MRF*HI\]OO$SRT\C`(*?=F1P%7@:F8JPL12*K'\"_N7V^[/RU*IM;7>YOWD!D
M%(F%?G&&#@?[;K']/OG<XPE;Z]Y<@_<[$4(DF0D'TE*LA/\`S;SZ#J[OX/?S
M)_CU\ZL964>P*S(;0[-P="N0W+U/O!J2'<M%0^1(9,Q@ZNEEDQ^ZMOQSR*C5
M-*1)`SH*B&`N@:`O<#VLYE]O9E?<E6?:I&TI<1UT$\=+@YC>F=+8-#I9J&F5
M/M5[W\F^[-NT>S.]OOD2:I+2:@D"UH70CMECJ15EHRU&M$U+7C_,!_F*=4_`
M79.$R>ZL77;Y['WM]^FP>M<-6T^.J\K%C/"N1SN=RU1%51[?VSCI*F.-ZCP5
M$TT[B.&)R)&C][;^V6\>XU_)%9NMOM<%/&G8%@NJNE$4$:W-":54`"K,,`Z]
MXO>CE[V@VJ*XW"-KK>KK5]/;(P4OIIJ>1R&\.,$@:M+,S&BJ0&*T[]7_`/"B
M3=,&^<+3_(3XTTNU.L]QRP34^XMCY7<,^XL1A:B81C/08K<N/IZ+>M!2H=4G
MV<M&SJ"8P[6C,W[M]V6T;;Y&Y:W4S;M$""DJH$9@/@+(:Q$^6H-3SH,]8U;#
M]]&]7=H4YQV-;?8IR")(7<R(C&@?3)VS`>>DQUH:5..M@C_9M/C?XO/_`*8-
MF^#_`$%?[,SYOOW\7^@G[W^&_P"DGR>'1_`?XC_D_P!?/YO1X]7'O&W^IG-%
M=/T4^K]X_0TI_P`2Z:O`X_'ISZ4S6G68G^N+R1IU_O*VT?NG]YUU&GT&K3]3
M6GP:NVGQ:L::]:M'_">W_LMGNK_Q`NZ__?G;`]Y=_>6_Y4*P_P"EC'_U8FZP
M`^YE_P!/2W/_`*5$W_:3:];@6Z=K[<WOMO.;/W?A,9N3:VYL76X3<&`S-)#7
MXK,8G(P/2UV/KZ.=7AJ*:I@D965A]#_7WA+:7=U874=[92/%>1.'1U-&5E-0
M01P(/72C<-OLMUL9=MW**.?;YXV22-P&1T8496!P00>M.7Y>?%/O?^3S\D-O
M_*;XO9+*U?1N6SKTV(JJMJO(T.WXLI.M1D.F.UHHF5LEMC,QQE<772,))EB0
MB1*^G263.#DKG#EWWNY6EY0YM1%YA2.K`44N5%%N;?\`AD7C(HP*G!C8J.:/
MN/[>\V_=JYXA]P>0GD;E.6:BDU81AC5[.Z`IJC<#]-R06`!U+-&'ZV=?A-\T
MNK/F_P!.X[LWKVJ3'9VA%+C.QNOZRJBFS^P-TO"SRXVO5`C56*KO$\V-KU18
MJVF%[)*DT,6)W/O(F\<@;XVT[F-5NU6AF`HDT=?B'HPP'2M5;U4JQSP]K/<_
ME_W5Y93?=F8)=J`MQ;D@O!+3X3PJC4)CDH`Z^2NKJNM+_+YRE%A/YV'R`S62
MF%/CL1NGYCY2OG/(@HL?GL_5U4Q^G$<$3-_L/>5/N5#)<>P^VP1"LKP[:H'J
M2D8`_:>L&/9BXBM?O1;W=3FD,=UO#L?15><D_D!TR?"_IVL_F_\`S^[A[Y[\
MFR.2Z@V554^Z<IM<5E5##58.KRE=C^I>HZ6IAD2;&[>@Q.-GJ,@8&26H6FF&
MI9:MI54\][VGLG[;V/+O+@5-[N`8UDH#1PH-Q<D<&<LP"5J`67BJ:2F]K^6I
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M_P!I=T=M5&4-=558IA+A5J%BIRNE3`36%MO-C(FZ;6J.K!TA1)FCBB@DJ68F
MFJ1I@>\$4`.FE.$I<Z\[>U/-%E?>V7N)N&Z;7?Q_2W.][A=;1#>;ONV]6:B%
M+&-5D2';K+:B@2`J]960RL=1[S\8GJ#Y8]^;.[@ZW^:E1\;J?J?M'K;+[-H-
MB=)XS?\`E-P8',99HXX<_D]Z;UJZ.DKIL1"&F@CI\?&!6I%*KJ(RK3V=[Y2Y
M=N-OW7DI=S_K!:7$<LDMRT(C;2*M&D<0)TLW;5FJ4J"*G'+0\M<]\VVV[[%[
MB/LW]4[ZVF@ABLTG,RAFI%-)+,P76JC7I1*"3258!>Z@O^3-VCNKX>_.;N+X
M-=LU)Q\>^\QF=JP0S2%*"'MKK@U\^&R-"TGH6CWWL\5`A<6-410@$^D>\D??
M/:+/G?V_L?<'9AJ-NBR&G'Z>:@93\XI--1^']3Y]8<_=CW_</;3W7W+VGYB.
MA+N1X@#72+JW+%&6OX9H]8!XN3#QQU:[_/`^4AZ`^'F5Z_P&2^SW_P#(JLJ.
MM\2()VAK:+924\=9V1F8O&ROXCA)(L43^'RRL/T^X=]@>4?ZR<[IN5RM=MVQ
M1.U1@RUI`OVZ@9/^;9'GUD)]ZOG_`/J=[:R;/:/IWC>F-L@![A``#<O]A0K"
M?^:U?+JA3>>U<Y\+OY2^S88DJL!VG_,/W[#F=VU"AJ3*4G0.Q\5-D=O[4!T+
M41TNY!DZ2MJ`K`2TN9D@D!''O(NQO+?GOWEG+4DVCEFWTQCBIO)6`>3TJFED
M'HT08=8B;IM]W[6_=VM@M8N8.<KH/,>##;X%)CC!XTD,B2G^*.8HU1CJQ[^5
MAO\`_E>_$3H_:&[-Z]\=,2?)?>^(I]P=@;CS9J:W/[+?*(*FDZ]P-3+B)C@J
M3;U&\<5<*9@U9D!*[N\8A6.+?=[;O=KG7F">SL=OOARK;N4A1:!)=.#,XU#6
M7-2FH=J:0`#J)F_[OVZ^P_MSRG:[CN6Z[:>=[J(23RN&:2'7D6Z'0=`1:"32
M>^3422H0*:_YB_(G^4O\S>H]Q=<=B_(_I5L]+BZT[#W]_EG]YM@[H$$AQ.9Q
M&6&&^^CHHJ[1]Y1A_MZVFUQ2*;@J#N1^6?>7D7>HMTVO:[[Z<./&AQX<T=>Y
M6752M*Z6I5&H0>I#]S.</N]>YW+D^R;UO.V_6&-OI[BC^+;RT['5_#U:=5-:
M5TNM5(X$5"?RDN]\[2?'_P#F+?%C*9A<IMR'XQ]R=N[,2.IEGH*')8S:65VC
MO5L+Y`+4&X8LIBZH`!06@:2P:1R9L]YN7;=^9>6.;X4T71W:VMI<4)5I%DBU
M?-"LB_[:G`#K&O[NO-]TG)G.OM_/+XED-AO;N`5)562%H9M!/E('B-*`=E:5
M8]2/Y5GR%KOBU_+Y_F+=U87PG=&VJ_JW&[-%0%:)=X[LQN7VIMJJ>)@5GBQF
M5S,=6\9XDC@9?S[I[O\`+,?-_N3RQL,]?I)5N&EI_OJ,I(XKY:E4J#Y$@]/^
MP/.<G('L[SIS1;D"^@>U2&N:33>+#$U//0[AR/,*1T8G^1Y\$MD=P8?=?S:^
M0F'@[/S^5WWGL5UOCM[0#/8^3,XZH2JWCV=FJ7)+44VX-P5^X:V6EI)*@2"F
MEIJB8*9GB>(,>_\`[AW^R3P\A<M2&TMDMT:=HCH;212.!2M"B!`&8+34&5?A
M#`C+[J?M+M?,MM<^Z?.<2WUY+=NMLLP\1=2D-+<N'J)',C%4+5TLKN:N5*[0
M^3P."S6(J=OYG"XG+8&LI30U>$R>.HZ_$55$R>,T=3C:J&6BGI3'Z3&R%+<6
MM[Q)BN;BWG%S!(Z7*FH=6(8'U#`@@_.M>L]I[.TNK9K.ZBCDLV724959"O#2
M5(*D4\B*=:?7\T7XX'^67\L.D?EI\58O[B[8W=G<EG,?M;&L\6"VOOC;#44V
MZ-ITM+&0(=C;_P!MY5E./),4:FLBC"0B*-,VO:3FC_77Y-W#DSG`_47<,:H9
M&^.2*2OAR$^<L+K\?$GPV-6J3S:]^^23[%>X>U>XGM\/I+"YE9UB7$<4\17Q
M(@!P@GC>GA\*&5!1`JB7_.8S&4KOD?\`"[YGU^R9=]?'_>G4O4.XL-B,JKR;
M:RTV*W17]C9WK?-58BFIJ.IW'MW/P$K(O^41/+I5Q#*JU]C((8^5]]Y$CG%O
MS)!>W*,R_&H:-8$G45!(1T/#@0M2-0KO[S=S<3<[\K^Z,MJ;ODVZVVSE1'J8
MG*2O<R6[FA"F2*1:U'<I:@.AJ71[-[Y_ED_S3]J;`V7N'^X^YL_MK*XO<N!Z
M:[%4;,W]M_,8V#[=L/C:".KH&W'A'@E\552XJIK<;60JHF1@@58(O^7?=?VA
MO+F^MOJ(K:5&1[F']6%U8UU,:'0]156D574UTG.<HMKYO]BO?[;[+;;SZ2>\
M@D26.SN/T;B-U%"B`%?%2AHZ0N\;"FH8`%B?^@3H[P_;?Z'>L/M_]'O^B7[?
M^XFV/#_HM_B'\6_T<^+^&:/[C_Q3_*?X7;[+[C]SQZ^?<8_UCY@U:_KKO5]3
M]17QI*_44T^/\7]KI[?$^*F*TZFG^J'*FCP_W98:/H_I*>!%3Z75K^FII_L-
M?=X7P:N[37/6IS_PGM_[+9[J_P#$"[K_`/?G;`]YD_>6_P"5"L/^EC'_`-6)
MNN=OW,O^GI;G_P!*B;_M)M>MR#W@[UTTZ1_8'7^S.U=E;FZY[$VYC-V[(WCB
M:K![EVYF(//C\IC*M=,L,J@I)%+&X62*:-DF@F19(V21%8+MMW*^V>_BW/;)
M7AOX'#HZFA5AY_/T(-002"""1T6[QL^V<P;7/LN\PI<;7<QE)(W%593Y>H(-
M"K`AE8!E(8`]:<W?/2/R)_DD?*K"=X](Y#)[GZ`WCE),;AZO)/-+A]R;=FF&
M0R737:GV\9BI\]1P1-)B\D%#SB%:NGTS1U,"9O\`+N_\L^_G)\G+^_JD/,D"
M:F"TU(X%%N;>N2A)HZ<!70W:48\T.;^5N=/NK\_Q<V<IN]QR=<R%4U5T21DZ
MGL[F@H)`!5'`[@HECHRNB)+^6?F:+Y$?S/.W-P8NDJL!C^\MH?+'+T%!73QS
M5N%I>RL?F*NGHZNJI@L4U1C8\R$>2,!69-0`O;VM]UH).6/:>QMIF$DFWS;>
MI(%`Q@9`2`>`;34`^M.BSV(NHN=??3=+RW5H8=V@W5U5C5D%TDQ`)'$J'H2.
M-*]&@_X3_=GXOI;Y`_(WXK=CF+;._P#>0Q2X2BR9%--5;PZ=K]UX?=FTH_*%
M9LJM#F9*N*(V+Q4,Y%RMB$OO(;1+OO+6U\X;767;8-6HKD"*Y6-HY/\`2U4*
M3ZNO0_\`N>\P0<L\Z;YR#O=+?>+HKH5L$S6C3"6'YOID9@/2)_.@ZG?.O^1U
M\GNW/EOV/VOTAN'KC,]?=U[UK=\9*LWEN.LV]E^O\ON!XY]PTN2QT&(R4F>Q
M$&0,DM')0L\[0N(GB0IK;FSOO(^Z7>[2W=BT;6\[EB6-"A/&HH:BO"F:8IU]
M1?L']^[VLY.]G]LY1Y[MMS@YBV.Q6U1;:%9H[N.$$0LCF1!%(4TK()0$#`NK
M$-I%EOS$W1AOY;/\JFAZAP?8N2I>P\9UC@>C>K=Q8S(5&%W5FM\UU-%%F]T;
M?-+5KDL3%A*-J[)J\<A%%''%%KU-'JR=]B.1WWCFO;=I:(7&U6($EP74-&40
M<'!J")'HH4UJ"?('KBO]]?WS_>5KS3[D2-^[]\YAO9?I(HG*R1M.^-#KI;5!
M`"SRBE74'#.HZ=OY(E?W=NKX:S=E=X[]W]V!E>Q^S]V9K9N3[!W'FMS9.'9&
M'H\+M6E6AK<Y5555#C*K<&"R,L<:,(SJ\@_63[%7O['L%GSR-JY?MK:VAM;2
M-95A1(U,K%Y#4(`"P1T!)SY>74.?=6EYJO\`VS.^<V7EY>7%[?RO"UQ))*P@
M18X@%,A+!3+'*0!CS''JM'^?+T+N+IGN[I/YZ=4"3"Y6MS6WMO[JS%`CJV+[
M/V$RYSKC<U4R^G5F,'BGH7)LI&*B1KF7F5?N[<QVV^[!?^W6\4DA6-WC4_B@
MF[)HQ_I78-Z_J$^74&?>YY0O.6.:=J]W>7ZQ3M-'',ZC*W,%'MY3ZEXTTYH!
MX`\VZ*GOKL7,_P`Z+^8UT=M/'XW+8;J7$;8VM29?%2CQOMS9N"QE'N_NO)R,
MCE(:G.;EFFP]%4%M4J"@N`QT@8[?M<'L3[7[A>2NDF\O+(5;^.5V,=JOS"H!
M(Z^7ZGEGJ/=TWRZ^]![U[3M\"21<NQ00AT_WU%&@FO'P<,TA>*-ZY_0J*XZ/
MQ_PHSZXJJ;J'XJ;MP&-6DVEL3=F]=@204=.(\=ASN;;6WZO;-,J(/'3TXI=C
M5$4:V"V4*/Q[CG[L&Z*^][Q97#ZKVXABFJ3EO#=Q(?F:RJ3U+WWU]C9.6^7]
MQM4T[99W$]N0H[5\6.)HU%.`TV[@>6*="%\/_P"4K_+@^3'QGZ9[KH=N;_R-
M9O;8N$JMSFD[4W'"E%O>AI4QF]L7)2T\_CHI,=NFCJXO$``JJ"!I(]E?.WO-
M[H\J\UWVPR2VZI!<,(ZVZ9B)U1-4C.J,J:_Y>COVU^[M[)<\\B[9S/%!=/+<
MVB&73<MVSJ-$ZT'#3*KBGI0C!'1CY?Y$7\NV&.2:;9_8T4,2/++++VSNB..*
M.-2[R2.]0%1$4$DD@`#V%Q]X;W-8A5GMBQX#Z>/_`#=#=ONE>RZ*6:UNPH%2
M3<O0#U/0$=0?'#^69M?H[YD=O?"#>DV[=Y8/XS_(KK7=,$_8N>SU7B\9-M7*
M-72U&UL_]O6ICLAD,!`]#DUA-+50^J"5U8GV(MZYH]UKOF'8]DY_@$-C)NUE
M/&?!1`S"1:`2)4:E#D/'74IPP%.@CR]R1[&;?RES-S'[5W/U&YQ;#N5M*/'9
MV5#"^HF)PK:6:-2DM"C#*L:]4S_$/KO-=C_RIOYD-'M^GGK,CM3=_0O83T=-
M&TLL^)V54UF:W"X1024H=OP552W]%@/N<^=-SM]K]X.5I+DA8IH;N&I\FE"J
MG[7TK^?6,OMWLEUOGW?N=X;,%IK>YL+@@>:0R2/*?L6/6Y_TO5[?\@7N+:^]
M?A6W5-'6TB;QZ8W]NRCSV'$B"M.#WOEZS>&W,^819FH<A+D:RD5^?WJ"0&W'
MO'G[Q^QW=ASY^^'4_0WUM&4;RU1*(G2OJ`JL1Z..LL_N>\R[?NGM;_5Z%@-R
MVR[E$B5[M$[F9)*?PLS2(#ZQGY=7E>\?NLK^M6W_`(4;=O;=R8^.OQZPL\65
MWO197<'9F>QM&5J*S%8_(T$>U-HT<L41>5:S<=7/7O'$0'*4JM8B1"<N?NP;
M)=1'<^9IP4L&1($8X#,I,DAJ<40:`3PJQ]#U@+]]?F2RG&R\F6Q$FZ+(]S(J
MY9%8".($"IK)^H:<:*#3N'5X?5?4_4Q^,W1?Q$[TH^O=XYJFZ&V'A\YU5O";
M!Y+(Y7^Z6U,+C,]DZ+;5;*V2E@PF4)45L$0:ED*LLB/8^X`WC>=Y_K7N/.G+
M[7,%NVXS,EQ&'55\21V12X[:NOX2>X5!!'657+O+O+PY#VCVXYK6SN;I-HMT
M>UF*,S>#"BR,L;'51&X.HJIH00>J(/YFW\F3JOI+J?>WRB^+F>SVR(>M(H-U
M[GZOR^7K,MBX</%D8(ZG+[`W-5RMN/"93!-4).M+55%6LL<;>*6&1423(?VH
M]]-WW_>(.4>;HX[@W1,<<ZJ%;5I-%F0=C*]"-2JM"14,"2,2O?7[L.P\K<OW
M7/OM]--:?14EEM7<NFC6*O!(?U%9"0VF1GJ`=+*0%:KO_AU[Y>_W9_A?^EK>
MG\=_V6K_`&7W^/?QVM\WW?\`I=_OA_I/^W\GVO\`I*_T<_[]K^-:/O\`P?O^
M3[C]SW+G^LWR5]7XWT<'T_[U^LT:!2GT_A>!6E?`\;]?PO@KVTTXZQ__`."+
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M4+)-33QK(C!E!]FNR;UN?+NZ0[SL\K0[A`^I6'\P1P96&&4U#`D$4Z(^9.6]
MFYNV2XY>Y@@6XVJY0JZ-_)E/%74T9'6C*P!!J.M;?X8?R_>P_@=_-FV9@LB:
M[<_3^[^O.XJGJCLIJ=5CS%##@:>:?;.XC`JTV/WK@89`*B(!(ZN("I@`1GCB
MRDY[]R=L]Q/9N>XCTQ;W!<VPN(*_"2]!(E<F)S\)XJ>QL@$X1>UWLWO'M%]X
M6WM9M4_+EU:79M+FGQJ(B3')3"S1@@.,!A1UP:*//\S_`/E';U[=[&E^6GPZ
MKXMO=WK5T.=WALFFRZ;3J-T[BPW@..WUL7<HFHJ;`;\1::/[E)YJ>"N>-9Q-
M%4>3[@.^TOO18;+M@Y,YW4R[!0I'*5\01HU=44J4)>+)TD!BH.G25II%OOU]
MW+=.9-Z/N)[:OX/-0(>6`/X1ED2A6:"2JB.;`U!F578"0,LFK61[%?S)?YTW
M3N./6N]OCYN'=^Y<;!'C*7<>]?CKOS);FD,:"*&H?)[(J,3MK<DQ4"U2(9?.
M?4[R$DF0)O:WV(WR3]ZV&YQ06KG44BO850?+3*&=/]+44X`#J*(/>_[T7+,/
M[CW39IKF]C`42S;=<-*:<"&A,<<F/Q:7U')+$]=]8?R[OY@W\RKN/"=P_/3+
M[OZYZRQIC#P;KIJ3;>Z9MOFHCJY]I=8]94L<:;(I\G<"?(U]-3L!^Z163*![
MUNWN;[:^U>QR;)[=)!=;J_G&2\8>E!)/.:^*5\D1F_A[%->K;#[+^\?OCS-#
MS-[NRW%GL4=,2@1RF.H8Q6]J`!"&\W=$'XB)6!!VTME;,VOUUM#;&PMDX6BV
M[M#9N"Q>VMM8+'QF.BQ6%PU'%0XZA@5BSLL%-"H+.6=S=F)8DG#2_OKO=+V7
M<;^1I;V>1G=VXLS&K$_:3]@X#'71+:MKL-DVV#9]JB6';;6%(HHUX(B`*JC[
M`.)J3Q))Z`WYB_'3"_*WXV=K]%9C[>&?>>VIQMK)SHK#!;TQ,D>7V?FU<JSQ
MI0;@HH#-HLSTQDCO9S[$')',\_)W--GS#!4K!*-:C\<3=LB_FA-*\&H?+H*>
MY?)5K[A<C[ARG<Z0]S`?"8\$G3OA?UH)%753)0LOGU49_(5^&N;Z6ZW[/[][
M+VY48/L7L3<>6ZVP&/R=.\.1P6R^NL]68G<5DD"O%_>+?N.G5P1^Y#B:>125
M<$S3]XKGF#?MTM.7-JE$FV6L2SNRFJO+,@9/MT0L"/0R,#D=8X_=$]L;GE78
M[_F[>H3%O%[.]M&K"C)#;R%9?F/$G4JPX?H*P-&ZN-^4'QRV!\L.D-\]%]D0
MS#`;QQZ)39:B2%LMMC<%!,E;M_=&&:=6C3)83)PQRJILDT8>&2\<C@P=RES1
MN7)V_P!OS!M9'U,#94UTR(</&U/PLI(]0:,,@=9,<^<E;1[A<JW?*>]@_1W*
M8=::XI%.J.5*_B1@#3@PJC=K$=:JNU^M/YL_\HW>.YL3U/LW+]P=,9?+M7N=
MN;2R_9W5VZ=)2"GSU5MO`5`WEUSN6HHX$CJ;-2:]`4R54<<;^\P;O=?9KWHL
M89MYG2RWU$IWR+!<1^90.X\*9`22N&]:(21USZL-B^\3]W'<I[?EVVDW+E>2
M2OZ<+W5K+Y"1HXSXUO(5`#9C)P"TBJIZ5?9/RG_G(?S",'4]);-^.^X>I]G;
MIA&'WA4;3V#N_KC'Y;&5@:*LHMR]E=G90QXK`U,+D5-/13P2U,.J)A*CM&R/
M:N4/8[VUN!O]]N<5Y?0G5&))HYV5AP*00+W.#\+,K!3D:2*@QWSG_P"\S[R6
MK<J[9LTVW;;.`DQBMYK971JAEEN;ER%0CXD5T+*"I#`Z3:3\7OY84'PT^$_R
M8P,*P=D_)?NCHKL;![ERFWZ5Y(/N*G8FX*7;766Q!5)!62XN/+5HUS2+#)DJ
MUUD=(TC@CBB+FSW9;GGG[:;EJVO*MAN$#(KG-!*A>>6E0&TC`%0B@@$DL3/O
M(?L.OME[5;[9)2^YYW3:;I)&C!(U-;R".V@K0E=9%6(4RO0D!515"S^1+\9>
MY^D.L_DUMGY"]/;IZ]BWSN+8R4&&WYAHZ6'<V&BVUN+'9N)*25YXZVB45JPS
MJPTD2:2""?9O]X7FS8M_W7:;OEJ]AN6MXY:M"U3&VN,J:C@<5'V=$?W3^0^9
M>5-DWVPYQVZ>T2[FATI/'02IHF5QI;XEHP#"E*-3HHG?O\LCYF_`SO7(?(_^
M6[D-P;EV563UM1_<C;KTF4WCM7$UU4M75['S6SLP\E+VAL990HH_&E17PK&F
MN(2PK5N->7/=CD7W$Y>7E?W16.*_4`>*]5BD8"@E65:&"6E=52J&IHVEB@C;
MG#V)]SO:3FU^=_9*2:?;'9CX$='FB1C4PO"]1<PUH%(5WP"RAT$K1JG^:W_.
M#W9C4Z_VU\0),-OZH5<<=RXOX\=OU.;BJV'B-7#AMPY&MVO1U/D]6JHAEIE(
MY32"/=U]G?9*SE.Y76]B3;AW:&O;8(1Z:D59"/\`2L&^?3+_`'A?O)[C`-GL
MN6S%NS=OB+MUX9`>&K1([QJ:YJR%?E3H=/Y?/\IKNW/]XT_S/_F#9*IS/8$6
M=@WIMOKG/Y6CW+N+)[OA$4N(W5V16T4E3AJ"EVVT<3XW"4CNL,L$7E$,<"TT
M@>]RO>38;;E\\B^VJ"/;3&8GG12B+&:AHX`:,2^0\K#(+:=1;6!=[.?=WYHO
M.:Q[G>\DAEWH3":.WD82R-,*%);@@E%6,@&.%22"JA@BIX;)+^8S\!_EMTM\
MM_\`AP#X10[FWEE,EF!NW<6W]O*=P[SV5NDT)H,^E+M>L>:;>776\*$R?<4%
M,D[T[5$\1@$!B=5GMA[C<F;[R7_K;\_&*")4\-'?LBECK5*R"@BFB-*,2`=*
MMJ+5'1?[U^T7N-RQ[B?Z\'M7X]S,\OC211CQ)H9=)$E(C4S03"M44.5UNA41
MZ3T6;N3Y3?S;OYA^S(_C%3?&',[+PNY)L92[\J-M]7[[V)2[ABH:ZEJ8X=W[
MP[&R<N$VOMU,A!%/40Q2P&4H$+.A,3"S8^4/9CVROSS8V[)//$&,(>XAF*5!
M'Z<<*AY'TD@$AJ5K0'/0#YEY_P#O&>\^V#D--BDM+:<J+AHK6>`2:6!`EEN'
M*1)J`8KJ2I%"2M5)B/\`H'[W3_=3^"_WYV;_`!O_`&5+^$?Q_P`V6O\`[-1_
MIG_O_P#<?9_P_3_HV_T??[]K[S7]Y;_*OMK_`+?L,_\`!)6GUGC_`$\_T_[X
MU:*+_P`D_P"E\&E=7]OXWZ^FFG\&OSZ&?_`<WGT'TWU5M]7_`%>T>)5O^2I]
M9X_PZ/\`<?Z;_%O$KK_T3PZ]O6TM[Q$ZS]Z][]U[KWOW7NO>_=>ZQO##(\,D
MD4<CT[M+`[HK/!(T4D#20LP)C=H960E;$JQ'T)][#,`0"0#Q^?GG\Q7JI56(
M+`$J:CY&E*CTP2/L/63WKJW7O?NO=>]^Z]U[W[KW7O?NO=<$C2-=$:)&MV;2
MBA%U.Q=VLH`N[L23^2;^]DDFIR>M`!110`.D!NOL"DVSG\#MP04E3D,U25^1
M9:S*+BDI\?05>,H7DBFFI)Z>HJIJG*((XGD@5EC?UZ]"/X"HKUNO3A3]A['J
MGK4I]U823^'4=3D:N45T(IHZ&B=(JZJ2K9A2SPT$LBI4&-V\#L%DTL0#ZAZ]
MURV[O?![JRF7QV#J8ZZ/#4.&JZFJB>VF7,39B-**>DD6.KI*F"/$B0B55+QS
MHRBQN?$4Z]U%RG8^T,'N.;;.9R]+B:VGPU/G)JG(S1T>/BI:K(#&TZ25D[I#
M'/-5,JJ"0&+``EC;WZA.1UJO4JFW_LJLK5QU/N;$25CTQJEB-6D:F)*,9&1/
M-)H@%3!CC]Q)"6\T<%Y&4("??J'KU1TT2=L["#8L4^?I:W^*YJCP4'VGDD:.
MJR%)5UM#/+&4644-9%1MX9P#'-]4+`,1[2>MU'3YO?=E%L?:^6W/D$\L&,@1
MEA,AA%14SS1TU)`TXBG,"2U,RJSZ'T*2=)M8^`J:=>Z::OLO:])293_<IC:O
M-8C"Y#*U6%H:[RO-/BL6^5KL915D\%-'4UD$$9+)I6:./UR1H+V]0_EU[K)#
MV1M58:5\ME*/"5%95Y2F@I*ZI3RB+&9FKPC5T[("E)0SU5(0LTI2(,=&K4"/
M?J'RZU4=*.'<FWZB?&4T&:QDM1FH,C4XF!*VG:;)4^(>&/*S448DUU,>.DJ8
MUG*@^(N`UK^]4ZWUA_O9MFU_X_B;?P+^]%_OZ?\`X]S5H_CO^<_XM6KCS_YO
M_'WNAZ]TH/>NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]T"O:^K[O&V+V_NYF/H"5O_`'VZPM?D"][6]V'6C_J_ET&6X?M1
MM7HPXK[)@N1@?'QCQIB9ZY*W%M3P926GUFEQ-1E0B5<R),\(8N(Y'41M8<37
MK6*#H3]N29YNT]_O)1;8AJVPO6"5]/19.LJ)(,0)>P;U,]8<32RU>8:;B*&2
M"&(4^D^4GCW4\!UOSZ9^S3"-X8P5L=(^*=>LOOY*Z7QPP3+W'MLXHQPO#+!5
MO/7D*=;P^)@C+Y"=*[7A_J]#UX]!'D'K?MLM#34^9$0[`[!?%Y'<%9GSAY,S
M_%MV2PT[X:JH%VC#4?Q1I(3-4U\E)]LIFFB]34Z;QU7I0X&;-MV'K;'9.&IM
MU6#3[BS6YJJI(U=IK4.:S*X"DI5IA!).R+00&E,T(4L/,7@]Y?M_R=6Z'7?;
M9%NOLN<E%209`BE\L>/GGJJ10,U2B$QS3T]'.^JG"E[QKI8L!<`$T''K?0*;
MJ>O/63PST^.3!ING>ST>0>LFDW1/5_>[P98)L,]#%24E?_$'FCR$J5TS_9QS
MOX]4C1Q6'Q?/JOEU*P;Y&.B[7&+I\#512X;*+F),_6S4#4$8RV^%AEBAIZ#)
M+EL(U(\S^.5Z(+51SH'(D:2+V,=>]>@WD4_;2#;TU8:T02#JUY*6):YMN^#<
MH[;>2-*MD7)"H:O**',9G3'C4`Y*;QY_ZO3KW^'HP?DVMXK_`&FV?/\`W%\>
BG^(5_B_T*?>Z?N]?\,U_>?P[U_;Z?#YO1YM/K]TZWCK_V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
